Search
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease.
The multicenter project, which yielded dozens of scientific papers on more than 30 different kinds of cancer, has officially drawn to a close.
Experts from Memorial Sloan Kettering presented some of the latest research on this challenging complication of many cancer surgeries.
Meet Paul Yoon, Program Coordinator of Spiritual Care at Memorial Sloan Kettering, who immigrated to the US from South Korea, survived cancer, and is navigating his concerns around violence against Asian Americans.
A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.
The combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) has shown improved progression-free survival (PFS) compared with chemotherapy as a first-line treatment for people with a high tumor mutational burden (TMB) in advanced non-small cell lung cancer (NSCLC). Data from the CheckMate -227 trial is being reported by Matthew Hellmann, MD, of Memorial Sloan Kettering Cancer Center, at the AACR Annual Meeting 2018. This research is featured in the meeting’s press program, and findings are being presented in the Clinical Trials Plenary Session, “Immunotherapy Combinations: The New Frontier in Lung Cancer.”
New research funds have been awarded by the RSNA Research & Education Foundation to Robert Young, MD for Using Functional MRI and Diffusion Tensor Imaging of the Language Pathway to Optimize Brain Tumor Resection.
Learn how MSK physician-scientist Christopher Klebanoff is working to bring immunotherapy to more patients, especially those with solid tumors.
Discover the significance of the Josie Robertson Surgery Center’s signature art piece.